Prelude Therapeutics Q3 2026 net loss narrows 36% to $12.54 million
PRLD•Prelude Therapeutics’ third-quarter net loss narrowed 36% year over year to $12.54 million, while revenue fell 13% to $5.65 million. The company reported $142.7 million in cash and securities at September 30 and expects its runway to extend into the second quarter of 2028.
1. Quarterly results and outlook
Third-quarter research and development expenses fell 32% year over year to $14.83 million. Prelude said PRT13722 began Phase 1 enrollment in the fourth quarter of 2026, with initial proof-of-concept data expected in the second half of 2027; a collaboration with Lilly will evaluate it with abemaciclib and imlunestrant in patients with HR+/HER2- breast cancer.




